Get the Stockscreener App
2.34
2.09%
-0.05
Oramed Pharmaceuticals Inc stock is traded at $2.34, with a volume of 149.15K.
It is down -2.09% in the last 24 hours and down -4.10% over the past month.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
See More
Previous Close:
$2.39
Open:
$2.33
24h Volume:
149.15K
Relative Volume:
1.44
Market Cap:
$95.95M
Revenue:
$2.70M
Net Income/Loss:
$5.53M
P/E Ratio:
21.27
EPS:
0.11
Net Cash Flow:
$-10.55M
1W Performance:
-1.27%
1M Performance:
-4.10%
6M Performance:
+0.86%
1Y Performance:
+0.86%
1-Day Range:
$2.29
$2.38
1-Week Range:
$2.29
$2.42
52-Week Range:
$1.82
$3.09
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Name
Oramed Pharmaceuticals Inc
Sector
Industry
Phone
646-844-1164
Address
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Compare ORMP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
2.34 | 98.00M | 2.70M | 5.53M | -10.55M | 0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.83 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.76 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.40 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
821.96 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.94 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-20-21 | Initiated | Canaccord Genuity | Buy |
| Feb-09-21 | Initiated | National Securities | Buy |
| Dec-03-20 | Initiated | Alliance Global Partners | Buy |
| Mar-11-20 | Initiated | Aegis Capital | Buy |
| Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-17 | Resumed | B. Riley FBR, Inc. | Buy |
| May-26-16 | Reiterated | FBR Capital | Outperform |
| Dec-01-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-19-15 | Initiated | FBR Capital | Outperform |
| Apr-13-15 | Resumed | MLV & Co | Buy |
| Jan-30-14 | Reiterated | Aegis Capital | Buy |
| Jan-08-14 | Reiterated | Aegis Capital | Buy |
| Jan-08-14 | Initiated | MLV & Co | Buy |
| Dec-03-13 | Initiated | Aegis Capital | Buy |
View All
Oramed Pharmaceuticals Inc Stock (ORMP) Latest News
Is Oramed Pharmaceuticals Inc. stock a top pick in earnings seasonJuly 2025 EndofMonth & Weekly Momentum Stock Picks - newser.com
Ranking Oramed Pharmaceuticals Inc. among high performing stocks via toolsEarnings Overview Report & Precise Trade Entry Recommendations - newser.com
How Oramed Pharmaceuticals Inc. (OJU1) stock correlates with oil markets2025 Top Decliners & Entry Point Confirmation Alerts - newser.com
What sentiment indicators say about Oramed Pharmaceuticals Inc. stockWeekly Investment Report & Community Trade Idea Sharing - newser.com
Published on: 2025-11-03 04:30:55 - newser.com
Applying sector rotation models to Oramed Pharmaceuticals Inc.July 2025 Spike Watch & Risk Controlled Daily Trade Plans - newser.com
Using Ichimoku Cloud for Oramed Pharmaceuticals Inc. technicalsDay Trade & Precise Buy Zone Tips - newser.com
What insider trading reveals about Oramed Pharmaceuticals Inc. stockJuly 2025 EndofMonth & Reliable Volume Spike Alerts - newser.com
Why Oramed Pharmaceuticals Inc. (OJU1) stock fits value portfolios2025 Risk Factors & Growth-Oriented Investment Plans - newser.com
Why Oramed Pharmaceuticals Inc. stock is a must watch in 20252025 Valuation Update & Community Supported Trade Ideas - newser.com
Is Oramed Pharmaceuticals Inc a good long term investmentMoving Average Strategies & Superior Growth Investment - earlytimes.in
Is Oramed Pharmaceuticals Inc. stock a defensive play in 20252025 Geopolitical Influence & Community Consensus Trade Signals - newser.com
Pattern recognition hints at Oramed Pharmaceuticals Inc. upsideQuarterly Profit Review & Detailed Earnings Play Alerts - newser.com
What does recent volatility data suggest for Oramed Pharmaceuticals Inc.July 2025 Closing Moves & Free High Return Stock Watch Alerts - newser.com
Will Oramed Pharmaceuticals Inc. benefit from macro trends2025 Year in Review & Reliable Volume Spike Trade Alerts - newser.com
How Oramed Pharmaceuticals Inc. stock reacts to global recession fearsMarket Activity Report & Weekly Chart Analysis and Guides - newser.com
Will Oramed Pharmaceuticals Inc. (OJU1) stock maintain strong growthEarnings Miss & Real-Time Volume Trigger Notifications - newser.com
Oramed Pharmaceuticals (NASDAQ:ORMP) Rating Increased to Hold at Wall Street Zen - MarketBeat
Is Oramed Pharmaceuticals Inc. (OJU1) stock resilient in recession scenariosWeekly Volume Report & Growth Focused Investment Plans - newser.com
Custom watchlist performance reports with Oramed Pharmaceuticals Inc.Weekly Volume Report & Real-Time Volume Trigger Notifications - newser.com
Can technical indicators confirm Oramed Pharmaceuticals Inc.’s reversal2025 Price Action Summary & AI Driven Price Forecasts - newser.com
What recovery options are there for Oramed Pharmaceuticals Inc.July 2025 Analyst Calls & High Yield Equity Trading Tips - newser.com
Will Oramed Pharmaceuticals Inc. stock continue upward momentumEarnings Miss & Real-Time Sentiment Analysis - newser.com
Will breakout in Oramed Pharmaceuticals Inc. lead to full recoveryJuly 2025 PostEarnings & Risk Managed Investment Entry Signals - newser.com
Tools to assess Oramed Pharmaceuticals Inc.’s risk profileJuly 2025 Technicals & High Conviction Buy Zone Alerts - newser.com
Oramed Pharmaceuticals Inc Stock (ORMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.29%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):